Conditioned market authorization in China on February 5, 2021

           l  The results of pre-clinical and clinical research trials were published in Science and The Lancet.

           l The Phase Ⅲ and real-world studies conducted in some other countries showed that  CoronaVac® is safe for adults at all ages ≥ 18. It also showed  a significant effect on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.

           lThe inactivated COVID-19 Vaccine, CoronaVac®, was recommended under WHO Emergency Use Listing (EUL).

           l  The annual production capacity is over 2 billion doses, and the vaccine has been approved to use by more than 40 countries around the world.

• SINOVAC’s EV71 vaccine Inlive® is approved for children aged from 6 to 71 months
  2021/06/12
• Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine
  2016/01/28
• Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine
  2016/01/04
• Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities
  2015/05/14
• Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project
  2014/04/24
• Sinovac’s EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
  2014/02/27
• Sinovac Files New Drug Application for EV71 Vaccine and Receives Filing Acceptance from Beijing Drug Administration
  2013/05/30
• Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
  2013/04/18
• Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease
  2013/03/14
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
  2012/06/26
• Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial
  2012/06/12
• Sinovac's EV71 Vaccine Phase I Clinical Data for the Prevention of Epidemic Hand, Foot, Mouth Disease Published in Vaccine
  2012/03/29
• Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease
  2012/01/10
• Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
  2011/11/09
• Sinovac Commences Phase II Clinical Trial for EV71 Vaccine
  2011/06/28
• Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
  2011/05/25
• Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
  2011/03/10